Aster Capital Management’s Rapport Therapeutics RAPP Stock Holding History
Bought
Maintained
Sold
Other funds holding RAPP
Aster Capital Management's RAPP Position: Q3 2026 in Review
Aster Capital Management reduced its Rapport Therapeutics (RAPP) stake by 65% in Q3 2026, selling an estimated $3.02K and leaving 38 shares worth $1.28K. The position accounts for ﹤0.01% of the portfolio, ranked #912.
Aster Capital Management first reported a position in RAPP in Q4 2024 and has held it in 4 quarters since. The position peaked at $9.1K in Q4 2025. 169 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.
- Aster Capital Management held 38 shares of Rapport Therapeutics worth $1.28K as of Q3 2026.
- Aster Capital Management sold 70 Rapport Therapeutics shares in Q3 2026, an estimated $3.02K.
- Rapport Therapeutics made up ﹤0.01% of Aster Capital Management's portfolio in Q3 2026, its #912 holding.
- Aster Capital Management first reported a position in Rapport Therapeutics in Q4 2024 and has held it in 4 quarters since.
- Aster Capital Management's Rapport Therapeutics position peaked at $9.1K in Q4 2025.
- 169 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.
Based on Aster Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.